NS Partners’s AbbVie ABBV Stock Holding History

NS Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.6M	Buy	+44,478	New	+$11.4M	0.5%	50

Other funds holding ABBV

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

NS Partners's ABBV Position: Q3 2026 in Review

NS Partners opened a new position in AbbVie (ABBV) in Q3 2026: 44,478 shares worth $11.6M. The stake represents 0.5% of the portfolio and ranks #50 among its holdings.

3,700 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

NS Partners held 44,478 shares of AbbVie worth $11.6M as of Q3 2026.
AbbVie was a new NS Partners position in Q3 2026.
AbbVie made up 0.5% of NS Partners's portfolio in Q3 2026, its #50 holding.
3,700 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on NS Partners's 13F filing for Q3 2026, filed 10 Nov 2026.